Cardiac Glycosides and Synthetic Cardiotonic Drugs

Albrecht, Hans; Geiss, Karl-Heinz

doi:10.1002/14356007.a05_271

Cited by 4 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The term “cardiac glycosides”—often used interchangeably with “cardiotonic steroids”—refers to a class of steroidal natural products exhibiting positive inotropic activity. 1 These molecules possess the capacity to increase the cardiac output through their inhibitory interaction with the extracellular surface of the membrane-bound sodium pump (Na + /K + –ATPase) through stabilization in the E2-P transition state, resulting in the increase of intracellular sodium concentration and the buildup of intracellular calcium concentration in the sarcoplasmic reticulum. This process ultimately results in a more powerful contraction of the mycocyte.…”

Section: Introductionmentioning

confidence: 99%

Development of a Concise Synthesis of Ouabagenin and Hydroxylated Corticosteroid Analogues

et al. 2015

View full text Add to dashboard Cite

The natural product ouabagenin is a complex cardiotonic steroid with a highly oxygenated skeleton. This full account describes the development of a concise synthesis of ouabagenin, including the evolution of synthetic strategy to access hydroxylation at the C19 position of a steroid skeleton. In addition, approaches to install the requisite butenolide moiety at the C17 position are discussed. Lastly, methodology developed in this synthesis has been applied in the generation of novel analogues of corticosteroid drugs bearing a hydroxyl group at the C19 position.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of a Concise Synthesis of Ouabagenin and Hydroxylated Corticosteroid Analogues

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Epothilones (A&B) (8) are the natural macrolides having similar action to paclitaxel; binds at or near the paclitaxel site on the β ‐tubulin subunit in the interior of the microtubule (Larkin & Kaye, 2006; Reichenbach & Hofle, 2008). Another common example is digoxin (11) , a cardiac glycoside obtained from the plants of the genus Digitalis (Albrecht & Geiss, 2000). Mankind is also grateful to plant kingdom for some of the useful drugs like vinblastine ( 10 ) and vincristine ( 12 ), isolates of Cathranthus roseus (Apocynaceae) for their use in the treatment of pediatric leukemia and Hodgkin's disease (Balick & Cox, 1996).…”

Section: Natural Products In Traditional Systemsmentioning

confidence: 99%

“…Nature explores its potential weapon to treat the blinding disease glaucoma by utilizing the alkaloid Pilocarpine (7) which can be extracted from the Pilocarpus jaborand (Mann, 1992). (Albrecht & Geiss, 2000). Mankind is also grateful to plant kingdom for some of the useful drugs like vinblastine (10) and vincristine (12), isolates of Cathranthus roseus (Apocynaceae) for their use in the treatment of pediatric leukemia and Hodgkin's disease (Balick & Cox, 1996).…”

Section: Natural Products In Traditional Systemsmentioning

confidence: 99%

Natural products: A lead for drug discovery and development

Chopra¹,

Dhingra²

2021

Phytotherapy Research

198

View full text Add to dashboard Cite

Natural products are used since ancient times in folklore for the treatment of various ailments. Plant‐derived products have been recognized for many years as a source of therapeutic agents and structural diversity. A literature survey has been carried out to determine the utility of natural molecules and their modified analogs or derivatives as pharmacological active entities. This review presents a study on the importance of natural products in terms of drug discovery and development. It describes how the natural components can be utilized after small modifications in new perspectives. Various new modifications in structure offer a unique opportunity to establish a new molecular entity with better pharmacological potential. It was concluded that in this current era, new attempts are taken to utilize the compounds derived from natural sources as novel drug candidates, with a focus to find and discover new effective molecules that were referred to as “new entities of natural product drug discovery.”

show abstract

“…Is the first animal toxin-based drug approved for human use in 1981 [23,24]. Digoxin is obtained from the plants of the genus Digitalis [25]. Captopril was inspired by a natural product (see main text for details).…”

Section: Introductionmentioning

confidence: 99%

Progress and Impact of Latin American Natural Product Databases

Gómez-García¹,

Medina-Franco²

2022

Preprint

View full text Add to dashboard Cite

Natural products (NPs) are a rich source of structurally novel molecules, and the chemical space they encompass is far from being fully explored. Over history, NPs have represented a significant source of bioactive molecules and have served as a source of inspiration for developing many drugs on the market. On the other hand, computer-aided drug design (CADD) has contributed to drug discovery research, mitigating costs and time. In this sense, compound databases represent a fundamental element for the CADD. This work reviews the progress toward developing compound databases of natural origin, particularly databases developed in Latin America, and their practical applications in the drug discovery area. We also survey the computational methods, emphasizing chemoinformatic approaches to profile natural product databases.

show abstract

Cardiac Glycosides and Synthetic Cardiotonic Drugs

Cited by 4 publications

References 40 publications

Development of a Concise Synthesis of Ouabagenin and Hydroxylated Corticosteroid Analogues

Development of a Concise Synthesis of Ouabagenin and Hydroxylated Corticosteroid Analogues

Natural products: A lead for drug discovery and development

Progress and Impact of Latin American Natural Product Databases

Contact Info

Product

Resources

About